U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H20FN2O4S.Na
Molecular Weight 438.448
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RAMATROBAN SODIUM

SMILES

[Na+].[O-]C(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4

InChI

InChIKey=JRBVAOJTPBHRQQ-XFULWGLBSA-M
InChI=1S/C21H21FN2O4S.Na/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26;/h1-6,8-9,15,23H,7,10-13H2,(H,25,26);/q;+1/p-1/t15-;/m1./s1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C21H20FN2O4S
Molecular Weight 415.458
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Ramatroban is a dual antagonist of thromboxane A2 receptor and PGD2 receptor. The drug was developed by Bayer and tested for the treatment of asthma and allergic rhinitis. In Japan ramatroban reached final approval and is being marketed under the name Baynas. In vitro studies have shown that the drug effectively inhibits smooth muscle cells contraction.

CNS Activity

Curator's Comment: Ramatroban and its labeled metabolites did hardly penetrate the blood-brain barrier.

Originator

Curator's Comment: # Bayer

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BAYNAS

Approved Use

Treatment of Allergic rhinitis.

Launch Date

2000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
85 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
126.9 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
349.6 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
103.7 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
211.1 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
237.2 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
689.1 ng/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
209 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
265 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
320.9 ng/mL
75 mg 2 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
302.5 ng/mL
75 mg 2 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
518.1 ng/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
749.8 ng/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
404.5 ng/mL
50 mg 2 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
457.9 ng/mL
50 mg 2 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
137.4 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
193.6 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
555.2 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
422.9 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
972.8 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1284.9 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3214.8 ng × h/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
996.6 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
884.8 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
1139.1 ng × h/mL
75 mg 2 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
1142.2 ng × h/mL
75 mg 2 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
1703.1 ng × h/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
2099.4 ng × h/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
1188 ng × h/mL
50 mg 2 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
1220.3 ng × h/mL
50 mg 2 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.93 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.79 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.95 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.21 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.03 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.33 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.45 h
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.17 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.52 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
2.63 h
75 mg 2 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
2.13 h
75 mg 2 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
2.54 h
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
2.31 h
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
2.34 h
50 mg 2 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
2.93 h
50 mg 2 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RAMATROBAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1.95%
RAMATROBAN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
75 mg 2 times / day multiple, oral
Studied dose
Dose: 75 mg, 2 times / day
Route: oral
Route: multiple
Dose: 75 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Participation of chemical mediators other than histamine in nasal allergy signs: a study using mice lacking histamine H(1) receptors.
2002 Aug 9
Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2.
2005 Sep 16
Involvement of cyclooxygenase-2 in allergic nasal inflammation in rats.
2006 Nov
Zwitterionic CRTh2 antagonists.
2011 Mar 24
Patents

Patents

Sample Use Guides

75 mg is administered orally devided in two doses, after breakfast and after dinner (or before going to bed).
Route of Administration: Oral
In Vitro Use Guide
Human airway smooth muscle preparations and lung strips were treated wuth 10(-6), 10(-7) and 10(-8) M of remetroban to inhibit U46619-induced contractions.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:59:17 GMT 2025
Edited
by admin
on Mon Mar 31 17:59:17 GMT 2025
Record UNII
5J3I129AXS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RAMATROBAN SODIUM SALT
Preferred Name English
RAMATROBAN SODIUM
Common Name English
9H-CARBAZOLE-9-PROPANOIC ACID, 3-(((4-FLUOROPHENYL)SULFONYL)AMINO)-1,2,3,4-TETRAHYDRO-, SODIUM SALT (1:1), (3R)-
Systematic Name English
Code System Code Type Description
CAS
1040405-44-4
Created by admin on Mon Mar 31 17:59:17 GMT 2025 , Edited by admin on Mon Mar 31 17:59:17 GMT 2025
PRIMARY
PUBCHEM
67027609
Created by admin on Mon Mar 31 17:59:17 GMT 2025 , Edited by admin on Mon Mar 31 17:59:17 GMT 2025
PRIMARY
FDA UNII
5J3I129AXS
Created by admin on Mon Mar 31 17:59:17 GMT 2025 , Edited by admin on Mon Mar 31 17:59:17 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY